×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ARQT – arcutis biotherapeutics, inc. - common stock (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ARQT
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/2
01:16 pm
arqt
Arcutis and Padagis Agree to Stay Patent Lawsuit
Medium
Report
Arcutis and Padagis Agree to Stay Patent Lawsuit
3/27
08:00 am
arqt
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
Low
Report
Arcutis to Present at the 24th Annual Needham Virtual Healthcare Conference
3/17
07:07 am
arqt
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age [Yahoo! Finance]
High
Report
ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age [Yahoo! Finance]
3/11
03:17 pm
arqt
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Jefferies Financial Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.
Low
Report
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Jefferies Financial Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.
3/7
08:00 am
arqt
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
Low
Report
Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology Meeting
3/6
07:08 pm
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average [Yahoo! Finance]
3/5
07:07 pm
arqt
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]
Low
Report
Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]
3/5
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
8.4%
arcutis biotherapeutics, inc. - common stock
2/25/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
8.4%
arcutis biotherapeutics, inc. - common stock
2/25/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
8.4%
arcutis biotherapeutics, inc. - common stock
2/25/2025
04:00 pm
arqt
arcutis biotherapeutics, inc. - common stock
BEAT
Report
8.4%
arcutis biotherapeutics, inc. - common stock
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
4/2
04:19 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Topper David Joseph
Low
Report
Form 144 Arcutis Biotherapeutics, Filed by: Topper David Joseph
4/1
04:08 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
High
Report
Form 144 Arcutis Biotherapeutics, Filed by: Welgus Howard G.
3/26
04:41 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Mar 24 Filed by: Watanabe Todd Franklin
Low
Report
Form 4 Arcutis Biotherapeutics, For: Mar 24 Filed by: Watanabe Todd Franklin
3/25
05:09 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd Franklin
Medium
Report
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd Franklin
3/24
04:20 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd Franklin
Low
Report
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd Franklin
3/20
06:27 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Mar 17 Filed by: Watanabe Todd Franklin
Low
Report
Form 4 Arcutis Biotherapeutics, For: Mar 17 Filed by: Watanabe Todd Franklin
3/20
05:04 pm
arqt
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd Franklin
Low
Report
Form 144 Arcutis Biotherapeutics, Filed by: Watanabe Todd Franklin
3/17
04:52 pm
arqt
Form 4 Arcutis Biotherapeutics, For: Mar 13 Filed by: Burnett Patrick
Low
Report
Form 4 Arcutis Biotherapeutics, For: Mar 13 Filed by: Burnett Patrick
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/19
Form 10-K Arcutis Biotherapeutics, For: Dec 31
33.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
1/31 Form 424B4 Arcutis Biotherapeutics, 15.3%
3/23 I-Mab (NASDAQ: ARQT) had its "buy" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $50.00 price target on the stock. 11.4%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Koppel Adam 6.7%
2/19 Arcutis to Present at the Cowen 40th Annual Health Care Conference 4.3%
4/21 Arcutis Announces Enrollment of First Patient in Phase 1/2b Study of ARQ-252 in Patients with Chronic Hand Eczema 3.4%
2/3 Form 4 Arcutis Biotherapeutics, For: Jan 30 Filed by: TURNER JOSEPH L 3.1%
2/7 Form SC 13D Arcutis Biotherapeutics, Filed by: Bain Capital Life Sciences Fund, L.P. 2.9%
2/6 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Heron Patrick J 2.4%
2/13 Arcutis Announces Enrollment of First Patient in Topical Roflumilast Cream Phase 3 Open Label Extension Study in Plaque Psoriasis 2.3%
TOP News Decliners
3/16
Arcutis Announces Inclusion of Children in On-going Pivotal Phase 3 Clinical Trials Evaluating Topical Roflumilast (ARQ-151) as a Potential Once Daily Topical Treatment for Plaque Psoriasis
-16.2%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
1/31 Form S-8 Arcutis Biotherapeutics, -5.4%
2/25 I-Mab (NASDAQ: ARQT) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $50.00 price target on the stock. -4.6%
4/27 Form 8-K Arcutis Biotherapeutics, For: Apr 23 -2.7%
2/28 Form SEC STAFF LETTER Arcutis Biotherapeutics, -2.0%
2/4 Form 4 Arcutis Biotherapeutics, For: Feb 04 Filed by: Watanabe Todd Franklin -1.6%
2/10 Form SC 13D Arcutis Biotherapeutics, Filed by: ORBIMED ADVISORS LLC -1.0%
3/4 Form 4 Arcutis Biotherapeutics, For: Feb 27 Filed by: Sun Ricky -0.3%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: